Irene Agodoa, MD, on Addressing GVHD Risks in Treating Hematologic Malignancies
The senior vice president and head of medical affairs at Orca Bio discussed how Orca-T has been developed to lower the risk of graft-versus-host disease.
Irene Agodoa, MD, on Assessing Orca-T for Safer Cell Therapy in Hematologic Malignancies
The senior vice president and head of medical affairs at Orca Bio discussed the initiation of the Precision-T phase 3 trial.